A hopeful sign emerged today for Matt Stewart, a writer and advocate who has been publicly documenting his battle with cancer. As he prepared to have the chemotherapy connection to his port removed, Stewart shared news of a significant drop in his cancer antigen (CEA) levels, offering a moment of optimism in his ongoing treatment.
Stewart announced the positive development in a personal update, noting that his CEA level had fallen from 13.4 to 7.4. A CEA level under 3 is generally considered normal, according to the American Cancer Society. This marks the lowest reading Stewart has seen since November, fueling his hope that the immunotherapy drug Keytruda is proving effective.
Immunotherapy and Keytruda: A New Approach
Stewart began immunotherapy treatment approximately three weeks ago. Immunotherapy is a type of cancer treatment that helps your immune system fight cancer, as explained by the National Cancer Institute. Keytruda (pembrolizumab) is a specific type of immunotherapy known as a checkpoint inhibitor. These drugs work by blocking proteins that prevent the immune system from attacking cancer cells.
While doctors initially indicated it would take six to eight weeks to assess the treatment’s impact, the recent blood test results provided an encouraging early indication. Stewart expressed cautious optimism, stating his “prayer” is that Keytruda is “working and killing all the cancer inside” him. He acknowledged the need for further observation to confirm the drug’s efficacy and its ability to provide him with more time.
Understanding CEA Levels as a Cancer Marker
Carcinoembryonic antigen, or CEA, is a protein that can be found in the blood of people with certain types of cancer. While not all cancers produce CEA, and elevated levels don’t always indicate cancer, it’s often used as a tumor marker to monitor cancer progression and response to treatment. Mayo Clinic details that CEA levels can be affected by factors other than cancer, so they are typically used in conjunction with other tests and imaging.
The significance of Stewart’s drop in CEA levels lies in the fact that it suggests the cancer burden in his body may be decreasing. However, it’s crucial to remember that CEA levels are just one piece of the puzzle. Doctors will continue to monitor Stewart’s overall health and conduct further tests to gain a complete picture of his response to Keytruda.
Stewart’s Public Journey and Advocacy
Matt Stewart has been open about his cancer diagnosis and treatment journey, sharing updates and insights with his followers. His willingness to share his experiences has resonated with many, offering a sense of community and hope to others facing similar challenges. His advocacy extends to raising awareness about cancer research and the importance of early detection.
The positive news comes as Stewart continues to navigate the challenges of cancer treatment. While the drop in CEA levels is a welcome development, he remains realistic about the road ahead. He understands that further testing and time are needed to determine the long-term effectiveness of Keytruda.
Stewart’s next steps involve continued monitoring and regular check-ups with his medical team. He will likely undergo further imaging scans and blood tests to assess the cancer’s response to treatment. The medical team will use this information to adjust his treatment plan as needed.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The coming weeks will be critical in determining the full impact of the immunotherapy. Stewart’s story serves as a reminder of the ongoing advancements in cancer treatment and the importance of hope and perseverance. We will continue to follow his journey and provide updates as they become available.
Share this story to spread awareness and support for those battling cancer. We welcome your thoughts and well wishes for Matt in the comments below.
Keep reading
